Pfiz­er’s once-a-week he­mo­phil­ia an­ti­body re­duces bleed­ing in PhI­II study

Pfiz­er’s once-a-week an­ti­body treat­ment for he­mo­phil­ia A and B helped re­duce bleed­ing events in pa­tients com­pared to their usu­al treat­ment of blood clot­ting fac­tor in­fu­sions, the phar­ma com­pa­ny an­nounced Tues­day morn­ing.

The open-la­bel Phase III study in­clud­ed 116 peo­ple with he­mo­phil­ia who were first treat­ed for six months with ei­ther reg­u­lar or on-de­mand in­fu­sions of fac­tor VI­II or IX — the clot­ting fac­tors that pa­tients with he­mo­phil­ia A and B are miss­ing. Then, both groups switched over to once-a-week treat­ment with Pfiz­er’s an­ti­body marstacimab for one year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER